Antihypertensive activity of Salvia elegans Vahl. (Lamiaceae): ACE inhibition and angiotensin II antagonism. 2010

Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
Centro de Investigación Biomédica del Sur, Instituto Mexicano del Seguro Social (IMSS), Xochitepec, Morelos, Mexico.

BACKGROUND Salvia elegans Vahl. (Lamiaceae), recognized with the popular name of "mirto" is widely used in Mexico for healing purposes, and also them as antihypertensive treatment. OBJECTIVE The high prevalence of this illness and the side effects of antihypertensive drugs conducted us to the evaluation of the Salvia elegans extract on angiotensin II action. METHODS The acute response of blood pressure to angiotensin II administration was measured in mice. We also tested in vitro the inhibitory effect on angiotensin convertase enzyme. Additionally, characterization of the pharmacological effect of the extract fraction was obtained. RESULTS We obtained dose-response curve for the administration of complete extract and extract fractions. Due to the hydroalcoholic extract (SeHA) treatment blood pressure decreased significantly from systolic dose of 0.75 mg kg(-1) (p<0.05) and even had an antihypertensive effect that was greater than that treatment with losartan. SeHA extract decreased the E(max) of the AG II hypertensive effect by about 20% in both systolic and diastolic pressures, treatment with losartan also decreased the same parameter between 6% and 8% for systolic and diastolic pressures, respectively. Fractions SeF8 and SeF8-8 showed similar levels of AG II ED(50) for both pressures compared with losartan, these fractions showed major compounds with maximum absorbance peaks at 221, 289 and 330 nm typical of flavonoids. In the inhibition assay the activity of angiotensin converting enzyme (ACE), the extract SeHA showed percentage inhibition (%IACE) of 50.27+/-5.09% (n=5). SeBuOH fraction is found to have greater inhibitory capacity of achieving a IACE 78.40+/-2.24% (n=5), which was similar to the values obtained in the presence of the SeF8-22 fraction (82.61+/-1.74%) and lisinopril (87.18+/-1.16%). The changes in the value of K(M) suggest that components of the extracts and fractions were recognized by the enzyme's active site. The main compounds of the fractions SeBuOH, SeF8-22 were by flavonoid and phenyl propanoid types, according to UV absorption spectra of the fractions. CONCLUSIONS The experimental results demonstrated the antihypertensive effect of Salvia elegans and it was due to the AG II antagonism and inhibition of angiotensin converting enzyme.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D007700 Kinetics The rate dynamics in chemical or physical systems.
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008813 Mice, Inbred ICR An inbred strain of mouse that is used as a general purpose research strain, for therapeutic drug testing, and for the genetic analysis of CARCINOGEN-induced COLON CANCER. Mice, Inbred ICRC,Mice, ICR,Mouse, ICR,Mouse, Inbred ICR,Mouse, Inbred ICRC,ICR Mice,ICR Mice, Inbred,ICR Mouse,ICR Mouse, Inbred,ICRC Mice, Inbred,ICRC Mouse, Inbred,Inbred ICR Mice,Inbred ICR Mouse,Inbred ICRC Mice,Inbred ICRC Mouse
D010936 Plant Extracts Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard. Herbal Medicines,Plant Extract,Extract, Plant,Extracts, Plant,Medicines, Herbal
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002855 Chromatography, Thin Layer Chromatography on thin layers of adsorbents rather than in columns. The adsorbent can be alumina, silica gel, silicates, charcoals, or cellulose. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Chromatography, Thin-Layer,Thin Layer Chromatography,Chromatographies, Thin Layer,Chromatographies, Thin-Layer,Thin Layer Chromatographies,Thin-Layer Chromatographies,Thin-Layer Chromatography
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response

Related Publications

Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
December 2021, Natural product research,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
January 2020, Mitochondrial DNA. Part B, Resources,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
March 2004, European journal of heart failure,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
January 1997, Regulatory peptides,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
January 1999, Revista espanola de cardiologia,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
June 2018, Drug development research,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
January 1973, Life sciences. Pt. 1: Physiology and pharmacology,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
April 1999, Journal of the American College of Cardiology,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
January 1987, Clinical and experimental hypertension. Part A, Theory and practice,
Enrique Jiménez-Ferrer, and Fidel Hernández Badillo, and Manases González-Cortazar, and Jaime Tortoriello, and Maribel Herrera-Ruiz
October 2013, Molecules (Basel, Switzerland),
Copied contents to your clipboard!